Imatinib Cipla (Imatinib)

Imatinib acts on malignant cells that express the BCR‑ABL fusion protein or related tyrosine kinases, providing targeted therapy for several hematologic and solid tumours.

• Chronic myeloid leukemia (CML): suppresses leukemic cell proliferation and induces remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by inhibiting BCR‑ABL driven growth.
• Gastrointestinal stromal tumor (GIST): blocks KIT/PDGFRA signaling to control tumor growth.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL tyrosine kinase, as well as KIT and PDGFRA receptors. By preventing phosphorylation of downstream substrates, it blocks proliferative signaling pathways, leading to apoptosis of malignant cells that depend on these kinases for growth and survival.

Adverse reactions may vary in frequency and severity. Patients should be monitored regularly for both common and serious events.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower limbs.
• Muscle cramps: intermittent, usually self‑limiting.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, may require hydration.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Neutropenia: significant drop in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiac failure: reduced left‑ventricular ejection fraction.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Interstitial lung disease: dyspnea and pulmonary infiltrates.

Imatinib requires careful monitoring and patient education to minimize risks.

• Monitor blood counts: check complete blood count regularly for neutropenia.
• Assess liver function: perform hepatic enzyme tests before and during therapy.
• Evaluate cardiac status: baseline and periodic echocardiograms for patients with cardiac history.
• Avoid use in severe hepatic impairment: dose adjustment may be required.
• Pregnancy and lactation: safety not established; discuss risks with a specialist.
• Store below 25°C: keep in the original pack, protect from moisture.

Imatinib is metabolized primarily by CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels.
• Protease inhibitors (e.g., lopinavir/ritonavir): can markedly raise imatinib concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): can exacerbate edema.
• CYP2C8 substrates (e.g., paclitaxel): potential altered clearance.
• Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.